The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20201474: KPCI Holdings Ltd.; Partners Group Access 822, L.P.
20201477: Fastly, Inc.; Signal Sciences Corp.
20201479: Thomas H. Lee Parallel Fund VIII, L.P.; Insurance Technologies Holdings, LLC
20201419: Clayton, Dubilier & Rice Fund XI, L.P.; HD Supply Holdings, Inc.
Neurometrix, Inc.
Under a settlement with the Federal Trade Commission announced in March 2020, the marketers of an electrical nerve stimulation device called Quell have agreed to pay $4 million and stop making deceptive claims that the device treats pain throughout the body when placed below the knee. They also will stop claiming the device’s efficacy is clinically proven and that it has been cleared by the FDA to treat pain throughout the body. In early September 2020, the FTC announced it was returning almost $3.9 million to defrauded consumers.